[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100264269":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":17,"centralContacts":17,"locations":19,"responsibleParty":31,"collaborators":17,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":37,"acronym":38,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":41,"maxAge":42,"enrollmentInfo":43,"targetDuration":17,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":17,"overallStatus":52,"whyStopped":17,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},{"fullName":5,"class":6},"Nantes University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"IBEROGAST","EXPERIMENTAL","Dose of 20 drops three times a day for 28 days, on constipation parkinsonian patients with disorders intestinal transit.",[13],"Drug: IBEROGAST",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":17},"DRUG",null,[9],[20],{"facility":21,"status":17,"city":22,"state":17,"zip":17,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":17},"Tiphaine Rouaud","Nantes","France","FR",{"type":26,"coordinates":27},"Point",[28,29],-1.55336,47.21725,{"lat":29,"lon":28},{"type":32,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100264269","phase-2-prove-of-concept-study-to-evaluate-the-efficacy-safety-and-tolerability-of-iberogast-in-the-treatment-of-bowel-troubles-in-patients-with-parkinsons-disease-100264269",false,"NCT02719496","Prove of Concept Study, to Evaluate the Efficacy, Safety, and Tolerability of IBEROGAST in the Treatment of Bowel Troubles in Patients With Parkinson's Disease","PHYTOPARK","Inclusion Criteria:\n\n* Patient 30 to 80 years\n* Parkinson's disease according to the criteria of the United Kingdom Parkinson's Disease Society Brain Bank\n* Presence of constipation defined by the Rome III criteria Functional constipation\n* Social assured Patient\n* Patients with signed consent\n\nExclusion Criteria:\n\n* Organic Affection colic\n* Constipation Drug\n* Other neurological disorder Parkinson's disease\n* Metabolic disease diabetes collagenoses\n* Severe renal or hepatic impairment\n* Pregnant or lactating women\n* Premenopausal women without contraceptive device effective\n* Regular and prolonged use of history (\\> 12 months) of laxatives irritants\n* Use of oral laxative treatment in the two weeks before the start of treatment, and refusal to stop these treatment during the course of the study\n* Taking treatment antabuse\n* Cognitive impairment compromising understanding or application instructions\n* Patient already included in a research protocol\n* Minors\n* Nobody protected by law","ALL","30 Years","80 Years",{"count":44,"type":45},45,"ACTUAL","INTERVENTIONAL",[48],"PHASE2","The main objective of this study is to evaluate the efficacy of STW5 Iberogast, over a 28-day period, for the treatment of constipation in parkinsonian patients suffering from gastrointestinal disorders.",[51],"Gastrointestinal Disorders in Parkinson's Disease","COMPLETED","2018-04-20",{"date":55,"type":45},"2018-04-24",{"date":57,"type":17},"2016-04",{"date":59,"type":45},"2018-04",{"name":5,"class":6},1]